Here's why the Avita Medical share price is tumbling 20% today

Shares in the healthcare company are tanking today, despite no fresh news out since last week.

| More on:
A man sits uncomfortably at his laptop computer in an outdoor location at a table with trees in the background as he clutches the back of his neck with a wincing look on his face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Avita Medical shares have copped a pounding today, down close to 20%
  • The dual-listed company released an update last Friday, but ASX investors seemed to be far more forgiving back then
  • It seems ASX investors might be following Avita's less-forgiving US investors today

It's been a fairly lacklustre start to the trading week for most ASX shares so far this Monday. At the time of writing, the All Ordinaries Index (ASX: XAO) has fallen by 0.21%. But let's talk about the plunging Avita Medical Inc. (ASX: AVH) share price.

Avita Medical shares are in freefall today. This ASX healthcare share has dropped by a precipitous 19.38% so far this Monday to $3.66 a share. That comes after Avita shares closed at $4.54 each last Friday.

It was even worse for Avita this morning too, with the shares hitting a low of $3.53 soon after market open. That was a drop of 22.25% at the time.

So what on earth is going on with Avita shares today that has this company losing so much value?

Why has the Avita Medical share price lost 20% today?

Well, Avita is a bit of a unique case on the ASX. The company is actually a dual-listed share, with its other listing being on the United States NASDAQ exchange – Avita Medical Inc. (NASDAQ: RCEL).

Last Friday, Avita released some financial results and guidance to investors, covering the three months to 31 March 2023. These results revealed a 40% increase in revenue for the quarter to $10.6 million, as well as a rise in gross profit margins to 84%.

The company also announced a major change in its leadership team. Chief commercial officer Erin Liberto has resigned from the company, while Terry Bromley and Debbie Gardener have been promoted to senior vice president of global sales, and senior vice president of global marketing and strategy respectively.

ASX investors reacted negatively to this news on Friday's session, sending Avita shares down by 5.42%.

But Avita's American investors were far more savage on Friday night (our time). Over on the NASDAQ, the Avita share price tanked by a nasty 22.94%.

It seems Avita's ASX investors might be taking a lead from their American counterparts today in the wake of Friday's far more savage reaction. This could explain the doubling down of selling pressure that we seem to be witnessing on the ASX today.

But shareholders arguably don't have too much to complain about. Even after today's savage selling, the Avita share price on the ASX is still up a whopping 90% in 2023 so far:

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

Read more »

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »